Petersen KU, Kops M, Heintze K.
Analgetika der WHO-Stufe 1 zur Behandlung von (Migräne-) Kopfschmerzen.
WHO step 1 analgesics in the treatment of (migraine) headache.
Pharmakon 5, 69-74 (2017).
www.ingentaconnect.com/contentone/govi/pmakon/2017/00000005/00000001/art00010

 

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM and Birkmann A.
Mathematical Modeling of Herpes Simplex Virus-2 Suppression with Pritelivir Predicts Trial Outcomes.
Science Translational Medicine 03 Feb 2016:Vol. 8, Issue 324, pp. 324ra15.
www.ncbi.nlm.nih.gov/pmc/articles/PMC4880060/

 

Klotz U, Koop H, Labenz J, Petersen KU (Petersen KU, Hrsg.).
PPI in der Offizin.
Sicherer Umgang mit nicht rezeptpflichtigen Protonenpumpenhemmern.
Dustri-Verlag Karl Feistle, München-Deisenhofen (2016).
www.amazon.de/PPI-Offizin-Sicherer-rezeptpflichtigen-Protonenpumpenhemmern/dp/387185509X

 

Petersen KU.
Rezeptfrei erhältliche Schmerzmittel.
Intensiv- und Notfallbehandlung 40 (Suppl): S1-S27 (2015).

 

Heintze K, Petersen KU.
The case of drug causation of childhood asthma: antibiotics and paracetamol.
Eur J Clin Pharmacol. (2013 Jun); 69(6):1197-209. doi: 10.1007/s00228-012-1463-7. Epub 2013 Jan 5
www.ncbi.nlm.nih.gov/pmc/articles/PMC3651816

 

Morgenstern ECA, Heintze K.
[Effectiveness of analgesic combinations in the self-medication.] Fixe Analgetika-Kombinationen, Viel besser als ihr Ruf?
MMW Fortschritte der Medizin (2013) 155(9):49-51.
link.springer.com/article/10.1007/s15223-014-0429-2

 

Buschmann H.
Tapentadol-from morphine and tramadol to the discovery of tapentadol.
Edited by: Fischer, J.; Ganellin, C.R.; Rotella, D.P
Analogue-Based Drug Discovery III (2013), 295-318.
onlinelibrary.wiley.com/doi/10.1002/9783527651085.ch12/summary

 

Petersen KU.
Koffein in Schmerzmitteln – Mär oder Medizin? [Caffeine in analgesics – myth or medicine?]
MMW-Fortschr Med 155: 109–114 (2013).
link.springer.com/article/10.1007/s15006-013-2541-1

 

Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Koegel B, Schiene K, Strassburger W, et al.
Mechanistic and functional differentiation of tapentadol and tramadol.
Expert Opinion on Pharmacotherapy (2012), 13(10), 1437-1449.
www.ncbi.nlm.nih.gov/pubmed/22698264

 

Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Fernández JA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C. Weiler H, Hauer-Jensen M.
Pharmacological targeting of the thrombomodulin–protein C pathway mitigates radiation toxicity.
Nature Med 18: 1123-1129 (2012).
www.ncbi.nlm.nih.gov/pmc/articles/PMC3491776/

 

Galle J, Kleophas W, Dellanna F, Schmid VH, Forkel C, Dikta G, Krajewski V, Fuchs W, Forst T, Pfützner A.
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.
Nephron Extra. (2012 Jan); 2(1):104-14.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3383235

 

Petersen KU, Labenz J.
Lactulose bei hepatischer Enzephalopathie: Mythen und Fakten.
Thieme Praxis Report 4: 1- (2012).
www.amazon.de/Lactulose-hepatischer-Enzephalopathie-Mythen-Fakten/dp/B00C8WNO4C

 

Buschmann H, Heintze K, Morgenstern E.
Paracetamol – ein moderner Klassiker unter falschem Verdacht [Acetaminophen – A modern classic under suspicion]
MMW-Fortschritte der Medizin (2011), 153, 128-136
publications.rwth-aachen.de/record/232788

 

Kops M, Paulus W, Heintze K, Petersen KU.
Paracetamol: altbewährt oder riskant?
Deutsche Apotheker Zeitung (2011) 151(7): 68-72.
www.deutsche-apotheker-zeitung.de/daz-az/2011/daz-7-2011/paracetamol-altbewaehrt-oder-riskant

 

Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, Lehmann U, Fuchs W, Forst T.
PIOfix-Study: Effects of Pioglitazone/Metformin fixed combination in comparison to a combination of Metformin with Glimepiride on diabetic dyslipidemia.
Diabetes Technol Ther. (2011 Jun);13(6):637-43.
www.ncbi.nlm.nih.gov/pubmed/21457065

 

Forst T, Weber M, Pfützner A, Kleine I, Löbig M, Hohberg C, Fuchs W.
C-Peptide and Intima Media Thickness in Type 2 Diabetes Mellitus Treated with Pioglitazone.
Diabetes Stoffw Herz (2011) 20: 65 – 68.
www.researchgate.net/publication/287414313_C-Peptide_and_Intima_Media_Thickness_in_Type_2_Diabetes_Mellitus_Treated_with_Pioglitazone

 

Petersen KU.
Pharmakokinetische Interaktionen und ihre Beurteilung. Klinische Betrachtungen zur Relevanz von Interaktionen der Protonenpumpenhemmer Omeprazol und Pantoprazol in der Selbstmedikation.
Med Monatsschr Pharm 34: 270-278 (2011).
www.medmopharm.de/archiv/verzeichnis/2011/08.html

 

Petersen KU.
Paracetamol und die Leber. Schäden bei zugelassenen Dosen?
Münchener Med Wochenschr – Fortschr Med 153: 137–142 (2011).
www.springermedizin.de/paracetamol-und-die-leber/10319378

 

Hanefeld M, Schaper F, Appelt D, Fuchs W.
Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
Horm Metab Res. (2011 Dec) 43(13):980-3.
www.ncbi.nlm.nih.gov/pubmed/22068809

 

Heintze K.
Hörschäden durch Analgetika: ein neues Problem?
Deutsche Apotheker Zeitung (2010) 150: 66-70.
www.deutsche-apotheker-zeitung.de/daz-az/2010/daz-10-2010/hoerschaeden-durch-analgetika-ein-neues-problem

 

Petersen KU, Labenz J.
Protonenpumpenhemmer: Standort 2010.
Verdauungskrankheiten 28 (Suppl. 1): S1-S62 (2010).
www.dustri.com/nc/article-response-page.html?artId=7720&doi=

 

Fischbach W, Darius H, Gross M, Koop H, Kruck I, Petersen KU.
Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonen¬pumpeninhibitoren (PPIs). Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoff¬wechsel-krankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK).
Kardiologe 4: 353-364 (2010) and Z Gastroenterol 48: 1-8 (2010).
leitlinien.dgk.org/files/2010_Positionspapier_Thrombozytenaggregationshemmer_Protonenpumpeninhibitoren_PPI.pdf

 

Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM.
5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice.
Pain (2009) 141, p. 239-247.
www.ncbi.nlm.nih.gov/pubmed/19118950

 

Petersen KU.
Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.
Arzneimittelforschung 59: 213-227 (2009).
www.ncbi.nlm.nih.gov/pubmed/19537521

 

Heal D J, Smith S L., Fisas, A, Codony X, Buschmann H.
Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Pharmacology & Therapeutics (2008) 117(2), p. 207-231.
www.ncbi.nlm.nih.gov/pubmed/18068807

 

Heintze K.
Diskussion um sichere Paracetamol-Dosierung.
Deutsche Apotheker Zeitung (2008) 148: 64-70.
www.deutsche-apotheker-zeitung.de/daz-az/2008/daz-29-2008/diskussion-um-sichere-paracetamol-dosierung

 

Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M.
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes Vasc Dis Res (2008) 5:298–303.
dvr.sagepub.com/content/5/4/298.long

 

Petersen KU, Labens J, Heintze K.
Pharmaka mit Wirkungen auf den Gastrointestinaltrakt.
Pharmakologie und Toxikologie, Ed. Estler CJ.
Schattauer Verlag, Stuttgart; p. 597 – 636; 6. Ed. (2007).

 

Friderichs E, Christoph T, Buschmann H.
Analgesics and Antipyretics
In: Ullmann’s Encyclopedia of Industrial Chemistry
Wiley-VHC, Weinheim, p 1-97 (2007).
onlinelibrary.wiley.com/doi/10.1002/14356007.a02_269.pub3/abstract

 

Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K.
Absorption, Metabolism, and Excretion of 14C-Labeled Tapentadol HCl in Healthy Male Subjects.
Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep; 32(3):163-9.
www.ncbi.nlm.nih.gov/pubmed/18062408

 

Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Mercé R, Holenz J, Heal D, Buschmann H, Pauwels PJ.
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.
British Journal of Pharmacology (2006) 148(7), p. 973-983.
www.ncbi.nlm.nih.gov/pmc/articles/PMC1751931/?report=classic

 

Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH.
The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Anesth Analg. 2006 Jan;102(1):146-50.
www.ncbi.nlm.nih.gov/pubmed/16368820

 

Winter W, Deubner R, Holzgrabe U.
Multivariate analysis of nuclear magnetic resonance data – characterization of critical drug substance quality of gentamicin sulphate.
J Pharm Biomed. Anal. (2005) 38: 833-839.
www.ncbi.nlm.nih.gov/pubmed/16087045

 

Detre E, BeekmanJ, Thomsen MB, Petersen KU, Vos M.
Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.
Br J Pharmacol 145: 397-404 (2005).
www.ncbi.nlm.nih.gov/pmc/articles/PMC1576153/pdf/145-0706203a.pdf

 

Hoie, LH, Morgenstern ECA., Gruenwald J., Graubaum H-J, Busch R, Lüder W, Zunft H-JF.
A double-blind, placebo controlled trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Soy phospholipids and fiber enhance the cholesterol-lowering effect of soy protein.
European J. of Nutrition (2005) 44 (2): 65-71.
www.researchgate.net/publication/8402722_A_double-blind_placebo-controlled_clinical_trial_compares_the_cholesterollowering_effects_of_two_different_soy_protein_preparations_in_hypercholesterolemic_subjects

 

Schindler C, Schweizer J, Müller A, Koch R, Hellner G, Fuchs W, Kirch W.
Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty. A randomised, placebo-controlled trial.
Clin Drug Invest 25 (2005) 89-97.
www.ncbi.nlm.nih.gov/pubmed/17523758

 

Kirshner, JR, Karpova, AY, Kops M, Howley PM.
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.
J Virol. (2005) 79: 9320-9324
www.ncbi.nlm.nih.gov/pmc/articles/PMC1168760

 

Bönner G, Fuchs W.
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Curr Med Res Opin 20 (2004) 597-602.
www.ncbi.nlm.nih.gov/pubmed/15140325

 

Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J.
Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review.
Advanced Therapeutics (2003) 20 (1): 50-78.
www.ncbi.nlm.nih.gov/pubmed/12772818

 

Malfertheiner P, Mössner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, Fuchs W.
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Aliment Pharmacol Ther. 18 (2003) 615-25.
onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01695.x/abstract;jsessionid=BAFC6847E84C0900B421C681B676EF09.f04t01

 

Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B.
Analgesics – In: Chemistry & Pharmacology to Clinical Application.
604 pages, Wiley-VCH, ISBN 3-527-30403-7, (2002).

 

Karpova AY, Trost M, Murray JM, Cantley LC, Howley PM.
Interferon regulatory factor-3 is an in vivo target of DNA-PK.
Proc Natl Acad Sci USA. (2002) 99: 2818-2823.
www.ncbi.nlm.nih.gov/pmc/articles/PMC122431

 

Rex A, Morgenstern E, Fink H.
Anxiolytic-like effects of Kava-Kava in the elevated plus maze test-a comparison with diazepam.
Progress of Pharmacology and Toxicology, 26 (2002) 26: 855-860.
www.ncbi.nlm.nih.gov/pubmed/12369257

 

Morgenstern, E, Stattmann A, Grosse-Siestrup C, Stahl K, von Bayer H.
Ergebnisse zur pharmakologischen Untersuchung von Substanzen im Modell der physiologischen ex vivo-Hämoperfusion der isolierten Niere, pp 451-452. In: Forschung ohne Tierversuche 2000,
Schöffl H, Spielmann H, Gruber FP, Appl H, Harrer F, Pfaller W, Tritthart HA. Ersatz und Ergänzungsmethoden zu Tierversuchen, Ed. H. Schöffl, H. Spielmann und H. A. Tritthart. Springer-Verlag Wien, New York (2000).
www.researchgate.net/publication/300046134_Erste_Ergebnisse_zur_pharmakologischen_Untersuchung_von_Substanzen_im_Modell_der_physiologischen_ex_vivo-_Hamoperfusion_der_isolierten_Niere

 

Trost M, Kochs G, Haller O.
Characterization of a novel serine/threonine kinase associated with nuclear bodies.
J Biol Chem (2000) 275: 7373-7377.
www.jbc.org/content/275/10/7373.long

 

Matthiesen T, Wöhrmann T, Coogan TP, Uragg H.
A review of the experimental toxicology of tramadol.
Toxicology Letters. (1998) 95: 63-71.
www.ncbi.nlm.nih.gov/pubmed/9650647

 

Gutser UT, Friese J, Heubach JF, Matthiesen T, Selve N, Wilffert B, Gleitz J.
Mode of antinociceptive and toxic action of alkaloids of Aconitum spec.
Arch Pharmacol. (1998) 357: 39-48.
www.ncbi.nlm.nih.gov/pubmed/9459571

 

Kögel B, Christoph E, Friderichs E, Hennies HH, Matthiesen T, Schneider J, Holzgrabe U.
HZ2, a selective kappa-opioid agonist.
CNS Drug Rev. (1998) 4: 54-70.
onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00041.x/abstract

 

Morgenstern, E.
Die antiphlogistische Wirkung von Bronchipret¨ und seiner Komponenten im Rattenpfoten-ödem-Modell. In: Bronchitis – Neue Erkenntnisse zu Wirkungen und Wirksamkeit von Arzneipflanzen.
Ed. R.W. März
Karger Verlag, Freiburg, 1-9 (1998)

 

Wnendt S, Finkam M, Winter W, Ossig J, Raabe G and Zwingenberger K.
Enantioselective Inhibition of TNF-a Release by Thalidomide and Thalidomide-Analogues.
Chirality (1996) 8: 390-396.
www.ncbi.nlm.nih.gov/pubmed/8900028

 

Harling RJ, Gopinath C, Matthiesen T, Ishibashi S, Iwakura K, Sumi N.
Four-week intravenous toxicity study of montirelin hydrate (NS-3) in dogs followed by 4-week recovery test.
J Toxicol Sci. (1995) 20 (Suppl 2): 215-236.
www.jstage.jst.go.jp/article/jts1976/20/SupplementII/20_SupplementII_215/_article

 

Matthiesen T, Wöhrmann T.
Chlormadinonacetat: Aspekte zur Toxikologie.
In: E-G Loch, G Schramm (Hrsg).
Chlormadinonacetat bei Androgenisierungserscheinungen. Stellenwert in der Praxis;
Stuttgart, New York, p. 29 – 36 (1995)

 

Burroughs MH, Tsenova-Berkova L, Sokol K, Ossig J, Tuomanen E, Kaplan G.
Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis.
Microb Pathog. 1995 Oct; 19(4): 245-55.
www.ncbi.nlm.nih.gov/pubmed/8825912

 

Wöhrmann T, Kögel B-Y, Schneider J, Matthiesen T.
The beagle dog as a predictor of gastrointestinal findings in humans caused by the prostacyclin analogue taprostene.
Exp Toxic Pathol. (1994) 46: 71-73.
www.ncbi.nlm.nih.gov/pubmed/8086790

 

Winter W, Frankus E.
Thalidomide enantiomers.
The Lancet (1992) 339: 365.
www.ncbi.nlm.nih.gov/pubmed/1346437

 

Straßburger W, Winter W, Steffens GJ, Günzler WA and Flohé L.
Computer Aided Protein Design: Three Dimensional Model Building of the Saruplase Structure.
in Supercomputer and Chemistry 2, U. Harms (Ed.),
Springer-Verlag Berlin Heidelberg, (1991) S. 159-166.
link.springer.com/chapter/10.1007/978-3-642-50175-3_12

 

Wöhrmann T, Matthiesen T, Beier H, Flohé L.
Immunhistochemical detection of Saruplase (recombinant single-chain urokinase-type plasminogen activator) in normal rat tissue.
Histochemistry. (1991) 96: 163-167.
link.springer.com/article/10.1007/BF00315988

 

Winter W.
Naxaprostene.
Drugs of the Future (1990) 15: 233-236.

 

Schurig V, Ossig J, Link R.
Evidence for a Temperature Dependent Reversal of the Enantioselectivity in Complexation Gas Chromatography on Chiral Phases.
Angew. Chem. Int. Ed. Engl. 28, 194 (1989).
onlinelibrary.wiley.com/doi/10.1002/anie.198901941/full